SmartNuclide® is a leading biopharmaceutical company focused on innovative nuclear medicine products for diagnosis and treatment. Founded in 2015, SmartNuclide® is dedicated to bringing new hope to patients worldwide through the development of groundbreaking radiopharmaceuticals. Their product portfolio includes radioactive isotopes for thyroid cancer, breast cancer, and tumor diagnostics and therapies.

With over 200 million CNY in funding from four rounds of venture capital, SmartNuclide® has established a proprietary technology platform for the discovery, development, and production of radiopharmaceuticals based on monoclonal antibodies. They have strategically developed a specialized pipeline of high-quality radiopharmaceuticals, encompassing more than 10 innovative diagnostic and therapeutic products. Their first product, a recombinant human thyroid-stimulating hormone for radioactive iodine therapy (SNA001), has already been submitted for market approval and is expected to be approved by the end of the year, addressing a treatment gap in mainland China.

Located in Suzhou Industrial Park, SmartNuclide® is at the forefront of clinical-stage biopharmaceutical research, bringing new hope to cancer patients through the discovery and development of innovative biologics for tumor imaging and treatment. For more information, please contact them at [email protected].